Becton Dickinson & Co (NYSE:BDX)
$ 221.9 -0.08 (-0.04%) Market Cap: 64.16 Bil Enterprise Value: 82.13 Bil PE Ratio: 37.36 PB Ratio: 2.48 GF Score: 85/100

Becton Dickinson and Co at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 05:00PM GMT
Release Date Price: $217.26 (-0.38%)
Unidentified Analyst

Thanks everybody for being here. I'm thrilled today to have Becton, Dickinson presenting for our next medical device company here at the BoA Healthcare Conference, Tom Polen and Chuck Bodner on behalf of the company as well as Adam from Investor Relations group. I want to thank you guys for being here. It's a real pleasure to having you. Wanted to cover a couple of topics. Tom, I don't know if you had any -- anything you want to kind of lead with or I can just jump right into Q&A.

Thomas E. Polen
Becton, Dickinson and Company - President & COO

Jump in.

Questions & Answers

Unidentified Analyst

I think the kind of things that I wanted to ask about were, since you guys just reported, maybe talk a little bit about the quarter and then talk a little bit more about the -- a little more about paclitaxel, a little more about long-term and strategy. And so we'll try to hit those 3 things in our time together here this morning.

The first thing I wanted to talk about in terms of just going

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot